GLP 1 is released from the gut in response to food onset, especially fiber-containing foods including whole grains, vegetables, lean meats, etc
Abstract Aims/hypothesis: Glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors are novel drugs which have recently seen rapid uptake in the treatment of type 2 diabetes and obesity
Several GLP-1 receptor agonists are available, with varying pharmacokinetic profiles and approved indications
Prescribers generally do not ask about alcohol in enough detail during GLP-1 visits, partly because appointment time is short and partly because patients underreport
Taneja et al., 2001)
Iwaoka M, Katakura A, Mishima J et al (2015) Mimicking the lipid peroxidation inhibitory activity of phospholipid hydroperoxide glutathione peroxidase (GPx4) by using fatty acid conjugates of a water-soluble selenolane